Refine by
Neurological Disorders Articles & Analysis
129 news found
Ace Therapeutics is a preclinical contract research provider engaged in metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases. ...
Ace Therapeutics is a preclinical contract research provider engaged in metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases. ...
This comprehensive collection provides researchers with a unique resource to study various neurological conditions and accelerate their investigations into neurological diseases and disorders. ...
Boston: Microneedle technology, driven by high demand in dermatologic procedures and its versatile applications in drug delivery, vaccine administration, and disease diagnostics, faces challenges in its complex manufacturing process. Ongoing research and numerous products in development make this market dynamic for newcomers entering the field. “According to the latest BCC Research study, ...
(Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced a new partnership with Perigon Pharmacy 360, a full-service, specialty digital pharmacy, to enhance accessibility, affordability and adherence for patients treating symptoms ...
Cognitive behavioral tests have wide applications in understanding neurodegenerative diseases and non-neurological disorders that often lead to cognitive dysfunction. These conditions pose significant challenges to patients' health and well-being. ...
(Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain, addiction and neurological disorders, today announced that Health Canada has authorized the use of Quillivant® ER (extended release) for the treatment of attention deficit hyperactivity disorder (ADHD) in children ages 6 to 12. ...
Securities and Exchange Commission relating to Semper Paratus’ previously announced proposed business combination with Tevogen Bio Inc, a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology. The Registration Statement contains a preliminary proxy statement and ...
(Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological disorders, today announced new data from a human abuse potential (HAP) study of cebranopadol (TRN-228) which suggest the investigational compound has significantly lower abuse potential compared to both schedule II and schedule IV opioids. ...
At just 1 pound and 12 ounces, her son, Sutton, arrived with life-threatening health issues, including hydrocephalus - a neurological disorder caused by an abnormal buildup of cerebrospinal fluid in the brain that affects more than one million ...
In addition to showing great promise in image-guided cancer therapy, PLGA-based drug delivery systems are widely used for other therapeutic applications such as vaccination or treatment of neurological disorders, inflammation and other diseases. CD Bioparticles now offers customers a range of PLGA nanoparticles with excellent biocompatibility and ...
(Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological disorders, today announced the appointments of Thomas Englese as chief commercial officer and Marc Lesnick, Ph.D., as chief development officer. ...
Amin Kassam, the CEO of Neeka, a true pioneer in novel surgical procedures, neurological disorders, and innovative health solutions, led the creation and development of the Neeka platform. ...
Leadership of Bened Life will be as follows: Professor Tsai - Chief Scientist Franklin Cheng - CEO David Lee - COO Carletus Willis - Head of Growth “I’m looking forward to merging with our US partners to develop a cohesive global brand that elevates gut-brain axis research to help both healthy people and those with neurological disorders live ...
TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit). ...
” Earlier this year, VeriSIM was awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to fund the AI-driven development of medications for substance use disorder (SUD). The company is also co-developing new drugs with Mayo Clinic in key disease areas, including oncology, hematology, bone/joint ...
On Day 1, these abnormal volume changes were 13% and 55% (p National Institute of Neurological Disorders and Stroke (NINDS). Dr. Afshin Divani, Associate Professor Neurology at the University of New Mexico commented, “We are pleased to have successfully completed this study of nVNS as a possible treatment for TBI and believe our data ...
NeuroPointDX, a business unit of Stemina Biomarker Discovery, today announced the company will present recent data from the Children’s Autism Metabolome Project (CAMP), its large, comprehensive clinical study, supporting its precision medicine approach to the diagnosis and treatment of autism spectrum disorder (ASD) at the National TACA Autism Conference. CAMP is the ...
LaunchPad Medical, Inc. announced that it has been awarded a $2.5 million Direct-to-Phase II Small Business Innovation Research (SBIR) grant (1R44NS115386) from the National Institute of Neurological Disorders and Stroke to advance the development of Tetranite®, its bone adhesive biomaterial technology, to improve cranial flap fixation procedures. ...
Many neurological conditions can be addressed with medications, but there is still significant unmet medical need. "Neurological disorders can be devastating to patients and their families, who are often left with few options," stated Larry Heaton, Chief Executive Officer of Flowonix Medical, Inc. ...